Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price ...

Eli Lilly was looking for infrastructure and an uncomplicated permit process for its $6.5M pharmaceutical manufacturing ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

India’s CDSCO has withdrawn Baricitinib’s COVID-19 use after Eli Lilly’s request, citing reduced need for emergency drugs.